Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells

Seok Gu Kang, Sin Soo Jeun, Jung Yeon Lim, Seong Muk Kim, Yoon Sun Yang, Won IL Oh, Pil Woo Huh, Chun Kun Park

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Mesenchymal stem cells (MSCs) represent a potential useful source for cell-based glioma therapies because these cells evidence both orthodox and unorthodox plasticity and also show tropism for cancer. In this study, the authors attempted to access the cytotoxicity of human umbilical cord blood (hUCB)-derived MSCs, with or without cytokine activations against malignant glioma cells. Materials and methods: hUCB-derived MSCs were activated by interleukin-2, interleukin-15, granulocyte macrophage colony-stimulating factor, and combinations. The hUCB-derived MSCs and activated hUCB-derived MSCs were effector cells. The cytotoxicity of the unactivated hUCB-derived MSCs and activated hUCB-derived MSCs against the target cells (human malignant glioma cells) was estimated via visual survival cell assays and transwell inserts. Phenotypic changes occurring in these hUCB-derived MSCs before and after cytokine activation were determined via flow cytometry. The secreted proteins from these effector cells were estimated via enzyme-linked immunosorbent assays. Results: We noted a significant cytotoxicity of hUCB-derived MSCs against malignant glioma cells. In addition, the hUCB-derived MSCs activated with cytokines evidenced significantly higher cytotoxicity than that observed with unactivated hUCB-derived MSCs. Differentiated immune effectors cells from the hUCB-derived MSCs after cytokine activation were not shown to have increased in number. However, the activated hUCB-derived MSCs secreted more immune response-related proteins (interleukin 4, interferon-γ) than did the unactivated hUCB-derived MSCs. Conclusion: The data collected herein confirm for the first time that hUCB-derived MSCs, with or without activation, evidence significant cytotoxicity against human malignant glioma cells, and the immune response-related proteins secreted in this process may perform relevant functions.

Original languageEnglish
Pages (from-to)293-302
Number of pages10
JournalChild's Nervous System
Volume24
Issue number3
DOIs
Publication statusPublished - 2008 Mar 1

Fingerprint

Mesenchymal Stromal Cells
Fetal Blood
Glioma
Cytokines
Interleukin-15
Proteins
Tropism
Granulocyte-Macrophage Colony-Stimulating Factor
Cell- and Tissue-Based Therapy
Interleukin-4
Interferons
Interleukin-2
Cell Survival
Flow Cytometry

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Kang, Seok Gu ; Jeun, Sin Soo ; Lim, Jung Yeon ; Kim, Seong Muk ; Yang, Yoon Sun ; Oh, Won IL ; Huh, Pil Woo ; Park, Chun Kun. / Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. In: Child's Nervous System. 2008 ; Vol. 24, No. 3. pp. 293-302.
@article{b77c5543b3af4948aa346130d5a5eecb,
title = "Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells",
abstract = "Background: Mesenchymal stem cells (MSCs) represent a potential useful source for cell-based glioma therapies because these cells evidence both orthodox and unorthodox plasticity and also show tropism for cancer. In this study, the authors attempted to access the cytotoxicity of human umbilical cord blood (hUCB)-derived MSCs, with or without cytokine activations against malignant glioma cells. Materials and methods: hUCB-derived MSCs were activated by interleukin-2, interleukin-15, granulocyte macrophage colony-stimulating factor, and combinations. The hUCB-derived MSCs and activated hUCB-derived MSCs were effector cells. The cytotoxicity of the unactivated hUCB-derived MSCs and activated hUCB-derived MSCs against the target cells (human malignant glioma cells) was estimated via visual survival cell assays and transwell inserts. Phenotypic changes occurring in these hUCB-derived MSCs before and after cytokine activation were determined via flow cytometry. The secreted proteins from these effector cells were estimated via enzyme-linked immunosorbent assays. Results: We noted a significant cytotoxicity of hUCB-derived MSCs against malignant glioma cells. In addition, the hUCB-derived MSCs activated with cytokines evidenced significantly higher cytotoxicity than that observed with unactivated hUCB-derived MSCs. Differentiated immune effectors cells from the hUCB-derived MSCs after cytokine activation were not shown to have increased in number. However, the activated hUCB-derived MSCs secreted more immune response-related proteins (interleukin 4, interferon-γ) than did the unactivated hUCB-derived MSCs. Conclusion: The data collected herein confirm for the first time that hUCB-derived MSCs, with or without activation, evidence significant cytotoxicity against human malignant glioma cells, and the immune response-related proteins secreted in this process may perform relevant functions.",
author = "Kang, {Seok Gu} and Jeun, {Sin Soo} and Lim, {Jung Yeon} and Kim, {Seong Muk} and Yang, {Yoon Sun} and Oh, {Won IL} and Huh, {Pil Woo} and Park, {Chun Kun}",
year = "2008",
month = "3",
day = "1",
doi = "10.1007/s00381-007-0515-2",
language = "English",
volume = "24",
pages = "293--302",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "3",

}

Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. / Kang, Seok Gu; Jeun, Sin Soo; Lim, Jung Yeon; Kim, Seong Muk; Yang, Yoon Sun; Oh, Won IL; Huh, Pil Woo; Park, Chun Kun.

In: Child's Nervous System, Vol. 24, No. 3, 01.03.2008, p. 293-302.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells

AU - Kang, Seok Gu

AU - Jeun, Sin Soo

AU - Lim, Jung Yeon

AU - Kim, Seong Muk

AU - Yang, Yoon Sun

AU - Oh, Won IL

AU - Huh, Pil Woo

AU - Park, Chun Kun

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: Mesenchymal stem cells (MSCs) represent a potential useful source for cell-based glioma therapies because these cells evidence both orthodox and unorthodox plasticity and also show tropism for cancer. In this study, the authors attempted to access the cytotoxicity of human umbilical cord blood (hUCB)-derived MSCs, with or without cytokine activations against malignant glioma cells. Materials and methods: hUCB-derived MSCs were activated by interleukin-2, interleukin-15, granulocyte macrophage colony-stimulating factor, and combinations. The hUCB-derived MSCs and activated hUCB-derived MSCs were effector cells. The cytotoxicity of the unactivated hUCB-derived MSCs and activated hUCB-derived MSCs against the target cells (human malignant glioma cells) was estimated via visual survival cell assays and transwell inserts. Phenotypic changes occurring in these hUCB-derived MSCs before and after cytokine activation were determined via flow cytometry. The secreted proteins from these effector cells were estimated via enzyme-linked immunosorbent assays. Results: We noted a significant cytotoxicity of hUCB-derived MSCs against malignant glioma cells. In addition, the hUCB-derived MSCs activated with cytokines evidenced significantly higher cytotoxicity than that observed with unactivated hUCB-derived MSCs. Differentiated immune effectors cells from the hUCB-derived MSCs after cytokine activation were not shown to have increased in number. However, the activated hUCB-derived MSCs secreted more immune response-related proteins (interleukin 4, interferon-γ) than did the unactivated hUCB-derived MSCs. Conclusion: The data collected herein confirm for the first time that hUCB-derived MSCs, with or without activation, evidence significant cytotoxicity against human malignant glioma cells, and the immune response-related proteins secreted in this process may perform relevant functions.

AB - Background: Mesenchymal stem cells (MSCs) represent a potential useful source for cell-based glioma therapies because these cells evidence both orthodox and unorthodox plasticity and also show tropism for cancer. In this study, the authors attempted to access the cytotoxicity of human umbilical cord blood (hUCB)-derived MSCs, with or without cytokine activations against malignant glioma cells. Materials and methods: hUCB-derived MSCs were activated by interleukin-2, interleukin-15, granulocyte macrophage colony-stimulating factor, and combinations. The hUCB-derived MSCs and activated hUCB-derived MSCs were effector cells. The cytotoxicity of the unactivated hUCB-derived MSCs and activated hUCB-derived MSCs against the target cells (human malignant glioma cells) was estimated via visual survival cell assays and transwell inserts. Phenotypic changes occurring in these hUCB-derived MSCs before and after cytokine activation were determined via flow cytometry. The secreted proteins from these effector cells were estimated via enzyme-linked immunosorbent assays. Results: We noted a significant cytotoxicity of hUCB-derived MSCs against malignant glioma cells. In addition, the hUCB-derived MSCs activated with cytokines evidenced significantly higher cytotoxicity than that observed with unactivated hUCB-derived MSCs. Differentiated immune effectors cells from the hUCB-derived MSCs after cytokine activation were not shown to have increased in number. However, the activated hUCB-derived MSCs secreted more immune response-related proteins (interleukin 4, interferon-γ) than did the unactivated hUCB-derived MSCs. Conclusion: The data collected herein confirm for the first time that hUCB-derived MSCs, with or without activation, evidence significant cytotoxicity against human malignant glioma cells, and the immune response-related proteins secreted in this process may perform relevant functions.

UR - http://www.scopus.com/inward/record.url?scp=39049105076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049105076&partnerID=8YFLogxK

U2 - 10.1007/s00381-007-0515-2

DO - 10.1007/s00381-007-0515-2

M3 - Article

C2 - 17968556

AN - SCOPUS:39049105076

VL - 24

SP - 293

EP - 302

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 3

ER -